6955 — Shandong Boan Biotechnology Co Income Statement
0.000.00%
Last trade - 00:00- HK$4.60bn
- HK$4.86bn
- CNY618.13m
Annual income statement for Shandong Boan Biotechnology Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 159 | 516 | 618 |
| Cost of Revenue | ||||
| Gross Profit | 0 | 107 | 354 | 409 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 229 | 373 | 834 | 723 |
| Operating Profit | -229 | -214 | -318 | -105 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -241 | -225 | -332 | -119 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -241 | -225 | -332 | -119 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -241 | -225 | -332 | -119 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -241 | -225 | -332 | -119 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.472 | -0.438 | -0.579 | -0.234 |